Democrats Meet With Trump to Discuss Drug Pricing
Representatives Elijah Cummings, D-Maryland, and Peter Welch, D-Vermont, met with President Donald Trump yesterday to form an unlikely alliance against the high cost of prescription drugs. The legislators presented a bill that would allow Medicare to negotiate prices, an idea that Trump had supported during his campaign. According to Kaiser Health News, Cummings commended the president as “aware of the problem” and “enthusiastic” in remarks after the meeting.
Replacement Bill Isn’t Called “Trumpcare,” White House Insists
The inevitable nickname of “Trumpcare” for the Republican bill to replace Obamacare has been greeted with resistance by the Trump administration, Politico reports. Democrats have seized on the term, but officials want the bill to be branded by its official name, the American Health Care Act, as they don’t want it associated with the negative connotations of Obamacare among conservatives. HHS secretary Tom Price offered up a slightly catchier alternative: “I prefer to call it PatientCare,” he said at a White House press briefing.
FDA Public Meeting Attempts to Define “Healthy” Foods
A battle that started over the word “healthy” on KIND bar labels has spurred the FDA to hold a public meeting in hopes of determining what actually makes a food healthy, reported STAT. Today’s meeting will unite nutritionists, food company representatives, and others to discuss topics like consumers’ perceptions of healthy foods and whether health claims should be based on nutrient content.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More